Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04089215 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma | unknown | Phase 2 | 82 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05747157 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Nov 21, 2023 | clinicaltrials |
| NCT05918198 | Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia | unknown | Phase 2 | 52 | Peking University People's HospitalOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06141304 | Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT | unknown | Phase 2 | 28 | The First Hospital of Jilin UniversityOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT04870853 | Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy | unknown | — | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT06130709 | IRAF-ABLATION Study: a Multicenter International Retrospective Cohort of Patients With BTK Inhibitors-related AF Treated by Catheter Ablation | unknown | — | 100 | University Hospital, CaenOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT03121456 | 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma(LYMPHODTECT) | unknown | N/A | 74 | Centre Antoine LacassagneOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05998928 | A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy | unknown | Phase 2 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06126237 | A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 120 | Keymed Biosciences Co.LtdINDUSTRY | 0 | Nov 13, 2023 | clinicaltrials |
| NCT05115292 | A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma | unknown | Phase 1 | 85 | BJ Bioscience, Inc.INDUSTRY | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06121765 | Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI | unknown | — | 45 | Assiut UniversityOTHER | 0 | Nov 8, 2023 | clinicaltrials |
| NCT04739826 | Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia | unknown | — | 491 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT06116734 | Lapelga vs Gastrofil | unknown | Phase 3 | 74 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 0 | Nov 3, 2023 | clinicaltrials |
| NCT06087419 | A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients | unknown | Phase 1 / Phase 2 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Nov 2, 2023 | clinicaltrials |
| NCT06111625 | Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL | unknown | Phase 2 | 20 | Sichuan UniversityOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT04519476 | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | unknown | Phase 1 | 22 | OncotherapeuticsINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06110182 | Evaluation of the Advantage in the Use of Enteral Nutrition in Children Treated for Acute Lymphoblastic Leukemia | unknown | — | 300 | Central Hospital, Nancy, FranceOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04767152 | Evaluation of Brain Changes in ALL Patients on Therapy | unknown | N/A | 110 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT06105658 | Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML | unknown | Phase 2 | 20 | Anhui Provincial HospitalOTHER_GOV | 1 | Oct 30, 2023 | clinicaltrials |
| NCT06106776 | CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study(CARdio-Tox) | unknown | — | 48 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Oct 30, 2023 | clinicaltrials |
| NCT06107478 | Parental Perception of Their Child's Emotional Quality of Life in Paediatric Oncology Before and After "Magic Massages"(MASSAYA) | unknown | — | 181 | Centre Leon BerardOTHER | 0 | Oct 30, 2023 | clinicaltrials |
| NCT05495828 | Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors | unknown | — | 30 | Peking University People's HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT04942067 | APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 108 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT04964518 | A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 24 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Oct 25, 2023 | clinicaltrials |
| NCT06056752 | QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 10 | Anhui Provincial HospitalOTHER_GOV | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05716919 | Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule | unknown | Phase 1 | 32 | Machaon Biotherapeutics, Inc.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05959694 | A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . | unknown | Phase 1 / Phase 2 | 107 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06026839 | Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors | unknown | — | 250 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06092203 | Quality of Life for Pediatric Urolithiasis(Elattar) | unknown | — | 100 | Mansoura UniversityOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05290090 | ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL | unknown | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06083701 | Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study | unknown | Phase 1 / Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT05504408 | Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid Leukemia | unknown | — | 200 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05510089 | Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies | unknown | N/A | 62 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06013683 | A Registry for Patients With Systemic Mastocytosis in China | unknown | — | 150 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06075212 | Immune Reconstitution After Allo-HSCT and Blinatumomab | unknown | — | 20 | Sichuan UniversityOTHER | 0 | Oct 10, 2023 | clinicaltrials |
| NCT03616782 | Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) | unknown | Phase 2 | 98 | Ho Sup LeeOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03697356 | R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia(Ballondor) | unknown | Phase 2 | 54 | Kosin University Gospel HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05329792 | L19IL2/L19TNF in Skin Cancer Patients(IntriNSiC) | unknown | Phase 2 | 70 | Philogen S.p.A.INDUSTRY | 3 | Oct 6, 2023 | clinicaltrials |
| NCT06067581 | the Safety and Efficacy of SENL103 Autologous T Cell Injection | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
| NCT05378971 | Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma | unknown | N/A | 15 | LanZhou UniversityOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT06067321 | Gastric Residual Volumes in Infants Fed at 4 and 6 Hours Prior to General Anaesthesia | unknown | N/A | 70 | King's College Hospital NHS TrustOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT04712864 | Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma | unknown | Phase 1 | 50 | Legend Biotech USA IncINDUSTRY | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04754035 | Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia(IMPROVE) | unknown | Phase 2 | 31 | Paolo GhiaOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04856215 | 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia(RITII) | unknown | Phase 2 | 25 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT06060080 | Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma | unknown | N/A | 7 | Yao LiuOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT06060431 | Effectiveness of a Pain Science Education Programme in Adolescent Students.(EDEA) | unknown | N/A | 293 | University Rovira i VirgiliOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT04693676 | A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma | unknown | Phase 1 | 17 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05768035 | Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide | unknown | Phase 1 / Phase 2 | 40 | Smart Immune SASINDUSTRY | 1 | Sep 25, 2023 | clinicaltrials |
| NCT06049381 | Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational Research | unknown | — | 22 | Ruijin HospitalOTHER | 0 | Sep 22, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 24, 2023source: clinicaltrials